{"nctId":"NCT01715415","briefTitle":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","startDateStruct":{"date":"2012-11"},"conditions":["Chronic Hepatitis C Infection"],"count":395,"armGroups":[{"label":"ABT-450/r/ABT-267 and ABT-333, plus RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333","Drug: Ribavirin"]},{"label":"Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267, ABT-333","Drug: Ribavirin","Drug: Placebo for ABT-450/r/ABT-267","Drug: Placebo for ABT-333","Drug: Placebo for ribavirin"]}],"interventions":[{"name":"ABT-450/r/ABT-267, ABT-333","otherNames":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ABT-333 also known as dasabuvir","Viekira PAK"]},{"name":"Ribavirin","otherNames":[]},{"name":"Placebo for ABT-450/r/ABT-267","otherNames":[]},{"name":"Placebo for ABT-333","otherNames":[]},{"name":"Placebo for ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control.\n* Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL at screening.\n* Previous treatment failure of peg-interferon and ribavirin (pegIFN and RBV).\n* No evidence of liver cirrhosis.\n\nExclusion Criteria:\n\n* Positive screen for drugs or alcohol.\n* Significant sensitivity to any drug.\n* Use of contraindicated medications within 2 weeks of dosing.\n* Certain predefined abnormal laboratory tests.\n* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period","description":"Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"12.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment","description":"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \\[HCV RNA\\] level less than the lower limit of quantitation \\[\\< LLOQ\\]) 12 weeks after the last dose of study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","description":"Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid \\[HCV RNA\\] ≥ lower limit of quantification \\[LLOQ\\] after HCV RNA \\< LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","description":"Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \\< LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":297},"commonTop":["HEADACHE","FATIGUE","NAUSEA","ASTHENIA","DYSPNOEA"]}}}